Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer
Background There are limited treatment options for patients with metastatic or recurrent cervical cancer. Platinum-based chemotherapy plus the anti-vascular endothelial growth factor antibody bevacizumab remains the mainstay of advanced treatment. Pembrolizumab is Food and Drug Agency approved for p...
Saved in:
| Main Authors: | Dmitriy Zamarin, Siqing Fu, Elad Sharon, Travis J Hollmann, Alexia Iasonos, Jason A Konner, Susan C Modesitt, Qin Zhou, Alexandre Buckley De Meritens, Carol Aghajanian, Claire F Friedman, Panagiotis A Konstantinopoulos, Bradley R Corr, Michael A Carducci, Alexandra Snyder Charen |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-10-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/8/2/e001126.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Evaluation of cardiovascular toxicity of the atezolizumab and bevacizumab combination
by: Takahiro Niimura, et al.
Published: (2023-08-01) -
Neoadjuvant atezolizumab plus bevacizumab prior liver transplantation for hepatocellular carcinoma
by: Parissa Tabrizian, et al.
Published: (2025-02-01) -
Atezolizumab and bevacizumab for hepatocellular carcinoma: How to approach salvage therapy for non-responders?: Editorial on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study”
by: Naoshi Nishida
Published: (2024-10-01) -
Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab
by: Meng Wu, et al.
Published: (2025-02-01) -
Effect of Proteinuria Before Lenvatinib Administration on Treatment Response After Atezolizumab Bevacizumab Combination Therapy
by: Hironori Ochi, et al.
Published: (2025-01-01)